Date: 08 Dec 2020

In this episode*, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases). With his current focus on AI digital pathology in assessing liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai speaks to us on the changing landscape of drug development for NASH fuelled by advances in AI digital pathology.

*This episode concludes Season 1 of Dialogues on AI Digital Pathology, and we will be commencing our second podcast season in mid-2021. Meanwhile, the webinars series on AI Digital Pathology in both NASH preclinical studies and clinical trials will commence in the first half of 2021. We’ll keep you posted on our webinars. Do remember to hit the Subscribe or Follow buttons at the following platforms to be updated when the Podcast’s Season 2 begins!